Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 May 2012
At a glance
- Drugs Panitumumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 04 Oct 2011 Actual initiation date (December 2011) added as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Mar 2011 New trial record